share_log

BioNTech | 6-K: Biontech and Dualitybio Receive Fda Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305

SEC announcement ·  Jan 31 07:51
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more